FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileMultiCell Technologies, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MCET
MultiCell Technologies, Inc. Stock AnalysisComprehensive stock analysis for MultiCell Technologies, Inc. (MCET) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMCET
MCET
MultiCell Technologies, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MCET
  1. Home
  2. Stocks
  3. MultiCell Technologies, Inc.

MultiCell Technologies, Inc.

🇺🇸MCET•OTC

MultiCell Technologies, Inc.

🇺🇸MCET•OTC
Market cap
$50.01K

Your view on MCET

Mkt Cap
$50.01K
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About MultiCell Technologies, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
W. Gerald Newmin
Headquarters
68 Cumberland Street, Woonsocket, RI, US
Industry
Biotechnology
Sector
Healthcare
CEO
W. Gerald Newmin
Headquarters
68 Cumberland Street, Woonsocket, RI, US
Description

MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications.

Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers.

The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004.

MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for MultiCell Technologies, Inc.. Starting points for MultiCell Technologies, Inc.: beta -35.68 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for MultiCell Technologies, Inc.. MultiCell Technologies, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for MultiCell Technologies, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for MultiCell Technologies, Inc.. MultiCell Technologies, Inc. has reported as a listed company since 2000. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold MCET18 companies
Compare MCET with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
HESGHealth Sciences Group, Inc.HealthcareBiotechnology$187,094
LLBOLifeline Biotechnologies, Inc.HealthcareMedical - Specialties$1.7M
NPHCNutra Pharma Corp.HealthcareDrug Manufacturers - Specialty & Generic$709,973
PSYBFPsyBio Therapeutics Corp.HealthcareBiotechnology$1,275
RGBPRegen BioPharma, Inc.HealthcareBiotechnology$37,866
ZIVOZIVO Bioscience, Inc.HealthcareBiotechnology$36.4M
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
FBIOPFortress Biotech, Inc.HealthcareNASDAQ$56.0M
FBLGFibroBiologics, Inc. Common StockHealthcareNASDAQ$6.3M
FDMT4D Molecular Therapeutics, Inc.HealthcareNASDAQ$576.8M
FENCFennec Pharmaceuticals Inc.HealthcareNASDAQ$462.1M
FGHQFFrontage Holdings CorporationHealthcareOTC$283.9M
FHTXFoghorn Therapeutics Inc.HealthcareNASDAQ$103.1M
FLNAFilana Therapeutics, Inc.HealthcareNASDAQ$31.0M
FNAMEvolutionary Genomics, Inc.HealthcareOTC$1,331
FNCHQFinch Therapeutics Group, Inc.HealthcareOTC—
FORUForU Holdings, Inc.HealthcareOTC$2,171
FPMIFluoroPharma Medical, Inc.HealthcareOTC$6,852
FRNMFreenome, Inc. Common stockHealthcareNASDAQ$76.4M
Open Comparable Analysis
Ownership & News

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by MultiCell Technologies, Inc. executives and directors. Shares of MultiCell Technologies, Inc. have traded between $0.0000 and $0.0000 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of MultiCell Technologies, Inc.

MCET AnalysisWeak
Past
5
Growth
1
Health
1
Profit
1
Value
1